Clinical trials: Cancer, Advanced
Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
This phase II trial studies how well ixazomib, gemcitabine, and doxorubicin work in treating patients with kidney cancer that has spread to other places in the body (locally advanced or metastatic).
- Conditions
- Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma, SMARCB1 Negative, Stage III Renal Cell Cancer AJCC v8
- Trial name
- NCT03587662
- Testing
- Doxorubicin, Doxorubicin Hydrochloride, Gemcitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Sorafenib in Treating Patients With Advanced Solid Tumors
This randomized phase I trial is studying the side effects, such as high blood pressure, and best dose of sorafenib in treating patients with advanced solid tumors.
- Trial name
- NCT00436579
- Testing
- sorafenib tosylate, pharmacological study, assessment of therapy complications
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer Stage IV
RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody
This is a retrospective, single-arm real-world study based on the National Anticancer Drug Clinical Application Monitoring Network database.The aim of this study is to evaluate the efficacy and safety of paclitaxel liposome…
- Trial name
- NCT06481553
- Testing
- first line treatment
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hematologic Malignancies, Acute Myeloid Leukemia
Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies
This study is not designed to test a hypothesis; rather, this study will provide patients with access to Orca-T if the commercial Orca-T product produced for them is deemed out of specification (OOS).
- Conditions
- Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT07346105
- Testing
- Orca-T
- Where
- 8 sites in United States
- Sponsor
- Orca Biosystems, Inc.
Non Small Cell Lung Cancer
Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS
This Phase II study consists of 2 parts: 1) pre-screening phase and 2) treatment phase. The pre-screening phase will investigate the presence of HRAS mutations in subjects with a histologically or cytologically confirmed…
- Trial name
- NCT03496766
- Testing
- Tipifarnib
- Where
- 30 sites in Spain
- Volunteers
- 9 people
- Sponsor
- Spanish Lung Cancer Group
Metastatic Breast Cancer
Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer
Long term efficacy of exemestane as compared to megestrol acetate in the treatment of women with natural or induced postmenopausal status with advanced breast cancer whose disease has progressed following anti-estrogens or…
- Trial name
- NCT01237327
- Testing
- Megestrol acetate, exemestane (Aromasin)
- Where
- 7 sites in China
- Volunteers
- 84 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).
This is a multicentre, non-interventional, prospective study to be carried out in representative oncology departments / institutions in order to determine the prevalence of EGFR mutations in treatment-naive Russian patients with…
- Trial name
- ORTUS (NCT02321046)
- Where
- 26 sites in Russia
- Volunteers
- 26 people
- Sponsor
- AstraZeneca
B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1)
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
This is an open-label, multicenter, Phase 1/2 study of tazemetostat as a single agent in subjects with advanced solid tumors or with B-cell lymphomas and tazemetostat in combination with prednisolone in subjects with diffuse…
- Conditions
- B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2), Follicular Lymphoma (Phase 2)
- Trial name
- NCT01897571
- Testing
- Tazemetostat, Prednisolone
- Where
- 52 sites in United States, Australia and 8 more
- Volunteers
- 400 people
- Sponsor
- Epizyme, Inc.
Breast Cancer
Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy
RATIONALE: Breast-conserving treatments such as radiation therapy or limited surgery are less invasive than mastectomy and may improve the quality of life.
- Trial name
- NCT00028704
- Testing
- conventional surgery, radiation therapy
- Where
- 13 sites in Belgium, Chile and 5 more
- Volunteers
- 26 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome
Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant/Preoperative Chemotherapy
The goal of this clinical trial is to learn if olanzapine works to prevent and treat anorexia-cachexia syndrome and appetite loss in cancer patients.
- Conditions
- Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome, Oncology
- Trial name
- NCT07633236
- Testing
- OLANZapine 2.5 MG
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Osteosarcoma, Osteosarcoma in Children
A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma
This is an open-label, unicentric, single-arm Phase 2 pilot study to serve as a proof-of-concept of OMO-103 safety and activity in patients with advanced high-grade osteosarcoma.
- Trial name
- Osteomyc (NCT06650514)
- Testing
- OMO-103
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Radiomic, Radiomics
RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
RADIOSPHER2 study is a monocentric, retrospective, observational study aiming at identifying a radiomics signature able to predict HER2 expression (0 vs low vs overexpression) and trastuzumab deruxtecan efficacy in metastatic…
- Conditions
- Radiomic, Radiomics, Breast Cancer Metastatic, Breast Cancer Stage IV
- Trial name
- RADIOSPHER2 (NCT07030569)
- Testing
- Trastuzumab deruxtecan (DS-8201a)
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Leukemia
New Therapy for Advanced Stage Leukemia After Stem Cell Transplantation
Hematopoietic stem cell transplantation (HSCT) is one of the best, and sometimes the only, option for the treatment of leukemia, particularly for patients with advanced-stage leukemia.
- Trial name
- NCT01455272
- Testing
- prophylactic GPBPCI
- Where
- 6 sites in China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Sarcoma
BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma
The aim of this study is to evaluate the efficacy and safety of Apatinib monotherapy for relapsed or refractory advanced bone and soft tissue sarcoma with VEGFR-2 (KDR) 604A>G polymorphism as predictive biomarker
- Trial name
- BIOVAS (NCT04072042)
- Testing
- Apatinib monotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
The purpose of this study is to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and yields a clinically compelling…
- Trial name
- NCT07430202
- Testing
- DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Small Cell Lung Cancer
Clinical Randomized Study of Concurrent Chemo-radiotherapy vs Radiotherapy Alone to Local-advanced Small Cell Lung Cancer (SCLC)
This trial aims to evaluate the efficacy and safety between radiotherapy alone and concurrent chemo-radiotherapy after 3-4 cycles of chemotherapy in LS-SCLC.
- Trial name
- SCLC (NCT01745445)
- Testing
- concurrent chemo-radiotherapy arm
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer
Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying vaccine therapy given after standard therapy to see how well it works in treating patients with stage…
- Trial name
- NCT00019929
- Testing
- mutant p53 peptide pulsed dendritic cell vaccine, adjuvant therapy
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Localised Prostate Cancer, Locally Advanced Prostate Cancer
MRI Guided Transurethral HIFU for Various Prostate Diseases
This study assesses feasibility and safety, the primary outcomes, of MRI guided transurethral high intensity focused ultrasound (HIFU) ablation for prostate diseases (PD).
- Conditions
- Localised Prostate Cancer, Locally Advanced Prostate Cancer, Locally Recurrent Prostate Cancer, Benign Prostatic Hyperplasia
- Trial name
- HIFU-PRO (NCT03350529)
- Testing
- MRI guided transurethral HIFU ablation of prostatic tissue
- Where
- Finland
- Volunteers
- 87 people
- Sponsor
- Turku University Hospital
Hepatocellular Carcinoma
Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma
In India, majority of our patients have advanced hepatocellular carcinoma (HCC) at presentation and hence are unsuitable for the available curative treatment options. In such patients the treatment options are mainly palliative.
- Trial name
- NCT02240771
- Testing
- Transarterial chemotherapy, Oral chemotherapy
- Where
- India
- Volunteers
- 124 people
- Sponsor
- All India Institute of Medical Sciences
Renal Cell Carcinoma
Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
The clinical outcome of advanced / metastatic renal cell carcinoma has been changed since targeted therapy being widely applied.
- Trial name
- NCT02776644
- Volunteers
- 1,349 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.